

# University of Illinois Cancer Center Winter CME Series – 2025

January 29, 2025 | Chicago, IL



This activity is jointly provided by Global Education Group and myMedEd, Inc.

## **Target Audience**

The series' target audience includes medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with cancer.

## **SESSION 3 DETAILS:**

JANUARY 29, 2025 – EMERGING PARADIGMS IN THE MANAGEMENT OF ONCOLOGY PATIENTS

## **Statement of Need/Program Overview**

Clinicians play a critical role in addressing health disparities by understanding the underrepresentation of minority populations in clinical trials and its impact on health equity and treatment outcomes. Additionally, as antibody-drug conjugates gain prominence in cancer treatment, clinicians must be well-versed in their mechanisms, patient selection criteria, and safe application. Education on biological cell engagers and adoptive cell therapies is essential, including their mechanisms, indications, and toxicity management. Furthermore, staying informed about emerging diagnostics such as liquid biopsy and minimal residual disease (MRD) testing is crucial for optimizing patient care and integrating these advancements into oncology practice.

## **Educational Objectives**

*After completing this activity, the participant should be better able to:*

- Explain the limitations of current registrational studies as they apply to minority populations and FDA guidance for proving this racial disparity (health equity)
- Describe the principles of antibody-drug conjugate therapy and current approved indications
- Discuss the principles of biological cell engagers/cell therapies and current approved indications
- Identify currently approved and emerging diagnostics for early cancer detection and minimal residual disease

## **SERIES COURSE CHAIR:**

Matias E Sanchez, MD  
Assistant Professor of Medicine  
Division Hematology/Oncology  
University of Illinois Cancer Center  
Chicago, IL

## **SESSION CHAIR:**

Ameen Salahudeen, MD, PhD  
Assistant Professor of Clinical Medicine  
University of Illinois Chicago  
Chicago, IL

**FACULTY PRESENTERS:****VK Gadi, MD, PhD**

Deputy Director, University of Illinois Cancer Center  
Professor and Director, Medical Oncology, UIC Department of Medicine  
University of Illinois Cancer Center  
Chicago, IL

**Kai He, MD, PhD**

Medical Oncologist  
Assistant Professor  
Thoracic Oncology  
Ohio State University Comprehensive Cancer Center  
Columbus, OH

**Rajat Thawani, MBBS**

Medical Oncologist  
Assistant Professor of Medicine  
Lung Cancer Specialist  
University of Chicago  
Chicago, IL

**Gayatry Mohapatra, MD, PhD**

Visiting Assistant Professor of Pathology  
Department of Pathology  
University of Illinois Chicago College of Medicine  
Chicago, IL

**Ryan Nguyen, DO**

Assistant Professor of Clinical Medicine  
Director, Precision Oncology Tumor Board  
University of Illinois Cancer Center  
Chicago, IL

**Program Agenda****AGENDA**

Day 3 – Wednesday, January 29, 2025

1:00 – 2:00pm – Registration, Exhibits and Lunch

2:00 – 2:05pm – Introduction

2:05 – 3:00pm – Innovative T-Cell Engagers and Adoptive T-Cell Therapies in Lung Cancer, Melanoma, and Soft Tissue Sarcoma (VK Gadi, MD – University of Illinois Cancer Center and Kai He, MD – Ohio State University Comprehensive Cancer Center)

3:00 – 3:40pm – Approved and Emerging Diagnostics for Early Cancer Detection and Minimal Residual Disease in Colon and Lung Cancer (Gayatry Mohapatra, MD – University of Illinois Cancer Center)

3:40 – 4:40pm – Breaks, Exhibits, Non-CME Ancillary Event, Afternoon Pick Me Up

4:40 – 5:25pm – Principles of Antibody-Drug Conjugate Therapy and Current Approved Indications in Lung and Ovarian Cancer (Rajat Thawani, MD – University of Chicago)

5:25 – 6:00pm – HEALTHY EQUITY - Discuss limitations of current registrational studies as they apply to minority populations and FDA guidance for proving this racial disparity (Ryan Nguyen, MD – University of Illinois Cancer

Center)  
6:00 – 7:00pm – Exhibits

### **Physician Accreditation Statement**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MyMedEd, INC. Global is accredited by the ACCME to provide continuing medical education for physicians.

### **Physician Credit Designation**

Global Education Group designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credit™* per session. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **ABIM MOC Recognition Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 and Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### **Instructions for Obtaining Credit**

To receive credit, participants must attend the activity in its entirety. Participants must also score at least 70% on the post-test and submit it with the evaluation. Upon completion of the evaluation, participants can claim credit and produce a certificate, which will be printable and emailed to the address provided on the form.

### **System Requirement**

Below is a table detailing the minimum requirements for streaming a Zoom Webinar across different platforms: Windows, macOS, iOS, and Android.

Platform	Operating System	Processor	RAM	Internet Speed	Additional Requirements
Windows	Windows 7 or later	Dual-core 2 GHz or higher (i3/i5/i7/AMD equivalent)	4 GB or more	1.5 Mbps (up/down) for HD	Webcam, microphone, speakers or headset. Updated Zoom app.
macOS	macOS X 10.10 or later	Dual-core Intel processor (M1/M2 supported)	4 GB or more	1.5 Mbps (up/down) for HD	Webcam, microphone, speakers or headset. Updated Zoom app.
iOS	iOS 8.0 or later	N/A	N/A	1.5 Mbps (up/down) for HD	iPhone, iPad, or iPod Touch. Zoom app from App Store.
Android	Android 5.0 (Lollipop) or later	N/A	N/A	1.5 Mbps (up/down) for HD	Smartphone or tablet. Zoom app from Google Play Store.

#### **Notes:**

- For best performance, use a wired internet connection for desktop/laptop or a strong Wi-Fi signal for mobile devices.
- Close unnecessary applications to optimize CPU and RAM usage during webinars.
- For webinars with high audience engagement (e.g., Q&A, polls), ensure you’re using the latest version of Zoom for enhanced features.

### **Fee Information& Refund/Cancellation Policy**

- Registration fee per session:  
Industry = \$200  
MD/DO = \$100  
APP = \$50

Students/Fellows = \$0.00

University of Illinois Chicago Staff, Faculty, and Affiliates = \$0.00

**Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Ameen Salahudeen, MD, PhD (Session Chair)	<b>Employee:</b> Tempus Labs - Ended 12/2023 <b>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):</b> Tempus Labs, Inc.
Gayatry Mohapatra, MD PhD	Nothing to Disclose
Kai He, MD, PhD	<b>Consulting Fee (e.g., Advisory Board)</b> Mirati Therapeutics, Perthera, Bristol-Myers Squibb, Iovance Biotherapeutics, Lyell Immunopharma, AstraZeneca, BeiGene, ONCO4, BioNTech, Obsidian, and Amgen. <b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Mirati Therapeutics, Bristol-Myers Squibb, Iovance Biotherapeutics, Lyell Immunopharma, AstraZeneca, BeiGene, ONCO4, AbbVie, Amgen, Genentech, and MSK.
Matias Sanchez, MD (Course Chair)	Nothing to Disclose
Rajat Thawani, MBBS	Nothing to Disclose
Ryan Nguyen, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Exelixis, Iovance <b>Speakers' Bureau</b> Pfizer, Merck, Bristol Myers Squibb

VK Gadi, MD

**Consulting Fee (e.g., Advisory Board)**

hologic, seagen (acquired by pfizer), pfizer, novartis, astrazeneca, stemline

**Contracted Research (Principal Investigators must provide information, even if received by the institution)**

agenda, gilead, novartis, astrazeneca, glaxo-smith-kline

**Speakers' Bureau**

stemline

**Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed)**

tempus

The **planners and managers** have the following relevant financial relationships with ineligible companies: The planners and managers at Global Education Group and MyMedEd have no relevant financial relationships to disclose.

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MyMedEd do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.